Coalition calls on US and Korea Trade Negotiators to prioritize public health over pharma corporations in trade negotiations

FOR IMMEDIATE RELEASE March 12, 2018 kim.treanor@keionline.org (202)-332-2670 A coalition of 16 advocacy organizations in the United States and Korea asked trade negotiators in the U.S. and Korea to reject the demands of the pharmaceutical industry, protect human rights, and… Continue Reading

KEI testimony at March 8, 2018 USTR Special 301 hearing, focusing on US compulsory licensing of patents

On March 8, 2018, USTR and the interagency committee on the Special 301 held a hearing. KEI was one of the groups testifying. More on this process here: https://keionline.org/ustr/special301 I began our oral testimony discussing President Trump’s promise, during the… Continue Reading

Trade Policy Reviews

KEI page on the World Trade Organization’s (WTO) Trade Policy Reviews All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes place in the “Trade Policy Review Body which is actually… Continue Reading

2000 Special 301 Report

2000 SPECIAL 301 REPORT United States Trade Representative Charlene Barshefsky today announced the results of the 2000 “Special 301” annual review which examined in detail the adequacy and effectiveness of intellectual property protection in over 70 countries. Ambassador Barshefsky also… Continue Reading

1999 Special 301 Report

OFFICE OF THE UNITED STATES TRADE REPRESENTATIVE Executive Office of the President Washington, D.C. 20508 For Immediate Release April 30, 1999 Contact: Jay Ziegler, Helaine Klasky, Amy Stilwell, (202) 395-3230 USTR ANNOUNCES RESULTS OF SPECIAL 301 ANNUAL REVIEW United States… Continue Reading

Wikileaks

Posted August 27, 2011 These are some tools for searching the US Department of State cables released by Wikileaks. A Wikileaks page on the cables is available here: http://wlcentral.org/cablegate KEI recommends this site for searching the cables by key words:… Continue Reading

PhRMA and BIO request EU be added to USTR Watch List over review of incentives

PhRMA and BIO have both requested that the US Trade Representative place the European Union on its watch list in the 2018 Special 301 Report. The Special 301 Report is a yearly review by the US Trade Representative of the… Continue Reading

PhRMA’s 2018 Special 301 Submission targets Australia, Canada, S. Korea, Japan & others over pricing, reimbursement policies

In its 2018 Special 301 submission, PhRMA targets a number of countries for pricing and reimbursement policies deemed hostile to the pharmaceutical industry. Among these, PhRMA strategically lobbies for the strongest classifications for Canada and Korea — countries dealing with… Continue Reading